Bisphosphonates and esophageal cancer-A pathway through the confusion

Nature Reviews Rheumatology

Volumn 7, Issue 6, 2011, Pages 369-372

  Dixon, William G ^a   Solomon, Daniel H ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ALCOHOL CONSUMPTION; BODY MASS; CANCER RISK; CONFIDENCE INTERVAL; ESOPHAGUS CANCER; FEMUR FRACTURE; FOLLOW UP; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; METHODOLOGY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC ERROR;

DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; HEALTH EDUCATION; HUMANS; PHARMACOEPIDEMIOLOGY; PUBLIC HEALTH; RISK FACTORS;

EID: 79958093375     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.60     Document Type: Review

References (18)

1. Cardwell, C. R., Abnet, C. C., Cantwell, M. M. & Murray, L. J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304, 657-663 (2010).
2. Green, J. et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341, c4444 (2010).
3. Watson, J., Wise, L. & Green, J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur. J. Clin. Pharmacol. 63, 843-849 (2007). (Pubitemid 47237896)
4. Lassen, A., Hallas, J. & De Muckadell, O. B. Esophagitis: incidence and risk of esophageal adenocarcinoma-a population-based cohort study. Am. J. Gastroenterol. 101, 1193-1199 (2006). (Pubitemid 43829981)
5. Daily Mail reporter. Drugs to fight bone thinning 'double the risk of cancer'. Daily Mail (London) (3 Sep. 2010).
6. Askling, J. & Dixon, W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 138-144 (2008). (Pubitemid 351339884)
7. Meier, C. R., Schlienger, R. G., Kraenzlin, M. E., Schlegel, B. & Jick, H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283, 3205-3210 (2000). (Pubitemid 30422037)
8. Van Staa, T. P., Wegman, S., De Vries, F., Leufkens, B. & Cooper, C. Use of statins and risk of fractures. JAMA 285, 1850-1855 (2001). (Pubitemid 32289152)
9. De Vries, F. De Vries, C., Cooper, C., Leufkens, B. & van Staa, T. P. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int. J. Epidemiol. 35, 1301-1308 (2006). (Pubitemid 44605555)
10. Solomon, D. H., Rekedal, L. & Cadarette, S. M. Osteoporosis treatments and adverse events. Curr. Opin. Rheumatol. 21, 363-368 (2009).
11. Herxheimer, A. Communicating with patients about harms and risks. PLoS Med. 2, e42 (2005).
12. Gigerenzer, G. Reckoning with risk: Learning to live with uncertainty (Penguin Books, London, 2003).
13. Calman, K. C. & Royston, G. Risk language and dialects. BMJ 315, 939-942 (1997). (Pubitemid 27425129)
14. Black, D. M. et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362, 1761-1771 (2010).
15. Gallagher, A. M., Rietbrock, S., Olson, M. & van Staa, T. P. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J. Bone Miner. Res. 23, 1569-1575 (2008).
16. Abrahamsen, B., Eiken, P. & Brixen, K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J. Intern. Med. 265, 581-592 (2009).
17. Kim, S. Y., Kim, M. J., Cadarette, S. M. & Solomon D. H. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res. Ther. 12, R30 (2010).
18. Loke Y. K., Jeevanantham V. & Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 32, 219-228 (2009).